查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1862520

乳癌筛检市场按技术、年龄层、实施方式和最终用户划分－2025-2032年全球预测

Breast Cancer Screening Market by Technology, Age Group, Delivery Mode, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，乳癌筛检市场规模将达到 91.5 亿美元，复合年增长率为 7.03%。

关键市场统计数据
基准年 2024 53.1亿美元
预计年份：2025年 56.9亿美元
预测年份 2032 91.5亿美元
复合年增长率 (%) 7.03%

全面介绍不断发展的乳癌筛检模式，重点关注技术、政策、临床实践和以患者为中心的就医趋势。

乳癌筛检处于技术创新、临床指南、政策改革和患者期望不断变化的交汇点，由此形成了一个动态环境，需要精准且基于实证医学的决策。影像技术、软体分析和医疗服务模式的进步正在重塑临床医生检测和管理早期疾病的方式。同时，法规结构和支付方的优先事项也在不断调整，以强调价值、疗效和公平获取。此外，不断发展的宣传宣传活动和风险分层方法也推动了对更灵敏、更微创、更人性化的筛检途径的需求。

在此背景下，筛检系统（包括製造商、医院系统、门诊中心、诊断连锁机构、软体供应商和支付方）必须应对各种相互衝突的压力：一方面，需要采用高性能技术来提高诊断准确性；另一方面，需要控製成本并与电子工作流程相整合；此外，还需要证明其临床效用和医护人员的准备。技术融合，包括先进影像重建技术、多平面视觉化和智慧演算法的集成，正在加速以往仅限于三级医疗中心的影像技术在临床上的应用。同时，云端交付模式和软体即服务 (SaaS) 选项正在降低高阶分析技术的普及门槛，并促进远距阅片和第二意见工作流程的发展。

本导言为深入探讨转型转变、监管和贸易逆风、细分市场趋势、区域差异、竞争行动以及旨在帮助高管、临床领导、产品团队和采购专家进行战略规划的实用建议奠定了基础，这些建议旨在帮助他们的组织获取临床价值、支持可扩展的服务模式并改善患者路径，同时不损害质量或合规性。

关键的变革性转变正在加速临床上对先进影像、人工智慧整合、个人化筛检路径和分散式云端医疗模式的采用。

过去几年，临床实践和市场动态发生了一系列变革性变化，重新定义了有效且公平的乳癌筛检。其中最显着的变化之一是容积成像和断层成像技术在临床实践中的快速应用。这些技术与先进的后处理和阅片流程相结合，显着提高了病灶的可见度，并降低了复检率。影像技术的进步与人工智慧 (AI) 和机器学习演算法的成熟相辅相成，进一步提升了放射科医师的诊疗水平，简化了分诊流程，并优化了分散式网路中有限诊断资源的分配。

另一个根本性的变化是筛检路径正朝着个人化、基于风险的方向发展。筛检方案不再采用千篇一律的筛检间隔或检测方法，而是越来越多地根据临床风险因素、遗传易感性和既往影像检查史等因素进行综合调整。这促使人们更加关注针对特定族群的辅助检测，例如对高风险族群进行对比造影磁振造影（MRI）检查，以及对传统乳房X光摄影受限的緻密型乳房族群采用分子成像技术。同时，检测模式也在不断发展。云端对应平臺和软体即服务（SaaS）产品正在加速进阶分析的去中心化，并实现远距离诊断；而自动化和照护现场硬体的改进则有助于扩大门诊中心和社区诊所的检测覆盖范围。

劳动力转型和临床培训也正在改变该领域的格局。随着诊断影像变得日益复杂，对跨专业协作、标准化报告和健全的品质保证系统的需求也随之增加。监管机构对互通性、资料隐私和临床获益证据的重视提高了新产品上市的标准，促使供应商提供更有力的真实世界证据，并更早与支付方接洽。这些变化正在塑造一个比以往更加技术主导、以患者为中心、更注重可验证结果的筛检环境。

美国关税于2025年生效的累积影响：对采购、製造地、供应链韧性和软体主导的临床连续性的影响

2025年美国关税政策对乳癌筛检价值链产生了一系列累积效应，波及筹资策略、供应商选择、製造地和临床实施时间表。关键子系统（例如检测器、数位影像撷取电子设备、专用帮浦线圈以及整合到先进成像平台中的半导体组件）进口成本的上升，迫使设备供应商重新评估供应链冗余和组件采购。这些压力促使一些製造商加快在地化生产并实现供应商多元化，同时压缩产品蓝图，并优先考虑模组化升级而非系统级更新。

医院、诊断中心和门诊医疗机构的采购决策者正在积极应对，尽可能延长设备的使用寿命，并协商签订多年维护和升级协议，以缓解近期资本成本的成长。同时，规模较小的独立诊断服务供应商正在探索替代交付模式，对云端基础的软体订阅和託管服务的需求日益增长，这些服务可以降低前期资本负担。此外，关税政策也凸显了软体主导的诊断增强功能的重要性，这些功能可以部署在现有硬体平台上，使医疗机构无需更换设备即可获得额外的临床价值。

监管机构和支付相关人员日益关注供应链中断对医疗服务取得和筛检计画连续性的下游影响。为此，一些医疗系统优先投资于临床培训、跨平台相容性以及关键备件的紧急储备，以维持服务的连续性。此外，关税带来的宏观经济讯号正在影响投资者和合作伙伴的行为，促使一些供应商重新评估其地理扩大策略，并在贸易条件更为有利的市场寻求製造合作伙伴关係。这导致製造商、服务供应商和医疗系统重新调整策略重点，更加强调韧性、软体主导的差异化和灵活的采购模式。

可操作的细分洞察揭示了不同实践环境中的特定模式发展轨迹、按年龄组分類的路径、交付模式差异以及最终用户采纳趋势

针对特定细分领域的趋势对于理解整个乳癌筛检流程中临床价值的创造点以及推广应用仍存在的障碍至关重要。技术细分揭示了清晰的推广应用轨迹：二维乳房乳房X光摄影（包括类比和数位技术）仍然是基础筛检方式，而三维断层合成技术正日益普及，以提高复杂乳房解剖结构的检测精度。磁振造影造影（MRI）持续运作，根据患者风险状况和临床适应症，引入了造影通讯协定和非造影技术。分子乳房影像（包括专用乳房伽玛成像和核子乳房摄影X光摄影）正作为辅助手段，在传统X射线方法难以处理的緻密组织病例中得到选择性应用。热成像和超音波发挥不同的作用，自动化超音波平台和携带式设备可作为互补的诊断手段，并有助于提高门诊和社区医疗机构的可及性。

基于年龄的细分凸显了差异化诊疗路径的必要性。年轻患者和40岁以下的患者通常需要进行影像诊断，这主要是基于症状评估或遗传风险。而中年患者通常是筛检的核心目标族群，其检查选择主要取决于乳房密度和先前影像检查史。对于老年人而言，平衡过度诊断风险和敏感度面临不同的挑战，需要更细緻的共用决策流程。交付方式的细分正在影响部署和营运模式。对于高通量影像中心和综合医院系统而言，本地部署解决方案仍然至关重要。云端解决方案，包括软体即服务 (SaaS) 和基于 Web 的平台，能够实现分散式阅片工作流程、集中式品管，并在无需大量资本支出的情况下逐步采用高级分析技术。最终使用者细分凸显了不同医疗机构采用驱动因素的差异：门诊中心、基层医疗和专科诊所、连锁和独立诊断中心以及公立和私立医院的采购週期、临床管治结构和报销环境各不相同。了解这些组合细分层对于设计产品策略、临床证据产生计划和市场推广方法至关重要，这些策略和方法应满足每个相关利益者群体的需求和限制。

深入分析美洲、欧洲、中东和非洲以及亚太地区在采用模式、报销环境和准入策略方面的差异化区域洞察

区域差异影响着医疗系统在乳癌筛检领域采用的技术、报销方式、人员配备和运作模式。在美洲，人们尤其重视将先进的筛检能力集中在整合医疗网路和大型诊断连锁机构中，同时，人们也越来越关注如何利用人工智慧驱动的阅片平台来管理大量患者并优化复检率。该地区的市场动态受到支付方模式的影响，这些模式奖励可验证的疗效，而集中式肿瘤计画则推动了对高风险族群高灵敏度检测的需求。

欧洲、中东和非洲地区呈现出多元化的格局，各国在监管标准、公共筛检计画结构和资源可用性方面存在显着差异。在部分地区，有组织的群体筛选计画和全民覆盖模式正在加速标准化通讯协定和品质保证框架的采用；而在其他地区，基础设施和人力资源的限制则推动了携带式、低成本检测方法和远端放射学服务的创新，以弥合服务获取方面的差距。

亚太地区汇集了众多实力雄厚的三级医疗中心，这些中心配备了最新的影像平台，同时社区层面的诊断服务也在迅速发展，优先考虑可及性和成本效益。在多个市场，公共卫生措施和不断壮大的私部门正同步提升筛检率，刺激了对云端工作流程、人工智慧驱动的分诊工具以及可在都市区和半都市区部署的可扩充性超音波解决方案的需求。在整个亚太地区，集中式专科医疗和分散式社区医疗之间的平衡将继续影响投资重点和伙伴关係模式。

透过整合、模组化升级、临床证据产生和云端服务模式，实现企业级差异化策略洞察

乳癌筛检生态系统的竞争动态由众多参与者所构成，包括影像设备製造商、专业软体供应商、云端服务供应商、託管服务公司和临床服务网路。领导企业凭藉整合解决方案脱颖而出，这些解决方案将硬体效能与先进的分析功能、强大的临床证据包以及全生命週期服务能力相结合，从而降低整体拥有成本。设备製造商与软体创新者之间的策略联盟已成为加速人工智慧功能上市、并透过合作研究弥合临床检验差距的有效途径。

企业发展的另一个主要趋势是注重模组化和可升级性，使客户能够在保留现有资本投资的同时，逐步采用更高级的功能。在资本支出预算受限且关税相关的采购波动使得软体主导的临床改善更具吸引力的环境下，这种方法尤其受到青睐。服务供应商和阅片管理供应商正在利用云端交付和订阅模式，提供可扩展的阅片能力、集中式品质保证和效能分析，这些对大型医院网路和独立诊断中心都至关重要。

最后，企业策略越来越注重实际影响和展现与支付方相关的成果。投资前瞻性临床研究、健康经济学分析以及与领先临床中心合作产生证据的公司，更有能力影响指南制定和支付方的核保决策。因此，我们看到，一些公司专注于功能上的渐进式改进，而另一些公司则追求深入的临床检验和整合式护理路径，以此作为持续差异化的手段，两者之间出现了分化。

为行业领导者提供切实可行的建议，以推动技术应用、增强韧性并加速验证其临床和支付方价值。

产业领导者若想在乳癌筛检领域维持并扩大其市场地位，应采取一系列务实且基于实证的行动，使商业性目标与临床重点和营运实际情况相符。首先，应优先进行前瞻性多中心研究，以产生临床证据，并以可靠的数据支持产品声明，这些数据应反映诊断效能、工作流程效率和后续临床影响，并与支付方的终点指标保持一致。其次，应采用模组化的产品和商业策略，使医疗机构能够逐步升级软体分​​析、人工智慧模组和云端服务等功能，而无需彻底更换成像系统。这将降低采用门槛，并有助于维护客户关係。

第三，透过多元化零件采购、探索区域製造伙伴关係以及开发服务模式来增强供应链韧性，从而最大限度地减少停机时间，并确保即使在中断期间也能持续提供诊断服务。第四，加速培训和变革管理专案的投资，以帮助放射科医生、技术人员和转诊医生整合新的技术和人工智慧辅助工作流程。这些投资将提高技术应用率、改善诊断一致性并提升患者满意度。第五，积极与监管机构、指南委员会和支付方合作，共用真实世界证据，并制定以价值和结果而非检测量为评估标准的报销模式。第六，促进整个生态系统（包括学术机构、专科诊所、诊断中心连锁机构和技术合作伙伴）的策略合作，共同开发临床路径、试点新的护理模式，并在典型的临床环境中检验价值提案。透过实施这些优先事项，产业领导者可以减少技术应用的障碍，展示可衡量的临床效益，并确保其产品和服务在各种医疗保健环境中持续应用。

透过结合二手证据、相关人员检验和三角验证的严谨混合调查方法，检验临床和商业性发现。

本分析的调查方法结合了定性和定量方法，以确保所得出的洞见具有稳健性、可重复性，并能为整个生态系统中的决策者提供参考。该方法首先基于同行评审文献、临床指南、监管文件、专利概况和公司资讯披露进行全面的二手研究，以建立背景基础并识别关键的技术、监管和报销趋势。随后进行一手研究，包括与各类相关人员（放射科医生、医院采购负责人、诊断中心经理、技术供应商、支付方和临床研究人员）进行结构化访谈和咨询，检验假设、揭示应用驱动因素并展现营运限制。

数据三角测量用于整合多元讯息，确保内部一致性。临床声明和产品特性与已发表的研究和专家意见进行交叉验证。建立细分框架，并透过相关人员的检验进行迭代完善，以反映跨技术、人口统计、交付模式和最终用户类型的真实决策流程。品质保证包括调查方法审核、与领域专家的同行评审以及对关键定性推论的敏感性检查。最后，将研究结果综合成可操作的叙述和策略要务，旨在支持采购决策、产品开发蓝图、临床应用策略和政策参与倡议。

最终的综合分析将整合技术、临床和策略方面的必要因素，以帮助相关人员有效推广筛检并改善筛检途径。

总之，在技术进步、数据驱动型解决方案的兴起以及强调个人化医疗和可衡量结果的临床范式转变的推动下，乳癌筛检正在经历一场深刻的变革时期。容积成像、人工智慧分析、多样化的服务模式以及日益精细的证据要求，共同为价值链上的相关人员带来了机会和挑战。专注于模组化、循证解决方案并投资于人才培养和供应链韧性的医疗服务提供者和供应商，将更有能力将创新转化为更早的检测和患者预后的持续改善。

未来的策略重点应放在将新功能整合到现有临床工作流程中，在相关患者群体中展现其相对临床价值，并制定能够反映长期治疗效果和系统层面效率的采购和报销框架。透过优先考虑临床检验、灵活实施、兼顾区域特殊性以及与支付方和政策制定者开展务实合作，相关人员可以应对挑战，扩大高性能筛检方法的普及范围，最终促进不同医疗体系中疾病的早期发现和患者预后的改善。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧驱动的乳房X光摄影演算法应用于临床，以提高诊断准确率并减少假阳性结果
  • 采用造影乳房X光摄影技术，以便更精确地显示緻密乳房组织中的肿瘤
  • 拓展液态生物检体筛检，用于非侵入性检测早期乳癌生物标记物
  • 透过在服务不足地区引入携带式超音波系统，改善即时乳房摄影服务的可及性
  • 开发用于乳癌筛检中循环肿瘤DNA分析的自采集套件
  • 政府采取措施，为高风险族群引入基于风险的个人化筛检方案
  • 整合远距乳房X光检查平台，以促进农村医疗机构的远距专家会诊
  • 一种基于深度学习的分流工具应运而生，旨在优先处理异常乳房X光摄影，从而减轻放射科医师的工作量。
  • 实施以价值为导向的报销模式，以促进早期发现和高品质筛检
  • 疫情后筛检延误消除计画：利用移动式乳房X光检查车解决筛检延误问题的措施

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章乳癌筛检市场（依技术划分）

  • 二维乳房X光摄影
    • 模拟
    • 数位的
  • 三维断层合成
  • 磁振造影
    • 使用造影
    • 非造影
  • 分子乳腺影像
    • 专用乳房伽玛成像
    • 核子乳房摄影
  • 热成像
  • 超音波
    • 自动化
    • 手持式

第九章 按年龄组别分類的乳癌筛检市场

  • 40-49岁
  • 50至69岁
  • 70岁或以上
  • 40岁以下

第十章 以交付方式乳癌筛检市场

  • 云
    • 软体即服务
    • 基于网路的
  • 本地部署

第十一章乳癌筛检市场（依最终用户划分）

  • 门诊治疗中心
  • 诊所
    • 基层医疗诊所
    • 专科诊所
  • 诊断中心
    • 连锁中心
    • 独立中心
  • 医院
    • 私立医院
    • 公立医院

第十二章 各地区乳癌筛检市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章乳癌筛检市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国乳癌筛检市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Hologic, Inc.
    • GE HealthCare
    • Siemens Healthineers AG
    • Koninklijke Philips NV
    • Fujifilm Holdings Corporation
    • Canon Medical Systems Corporation
    • Konica Minolta, Inc.
    • Shimadzu Corporation
    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • Carestream Health, Inc.
Product Code: MRR-521BAA36EB3C

The Breast Cancer Screening Market is projected to grow by USD 9.15 billion at a CAGR of 7.03% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.31 billion
Estimated Year [2025] USD 5.69 billion
Forecast Year [2032] USD 9.15 billion
CAGR (%) 7.03%

Comprehensive introduction to evolving breast cancer screening paradigms highlighting technology, policy, clinical practice and patient-centric access dynamics

Breast cancer screening is at the intersection of technological innovation, clinical guidelines, policy reform, and shifting patient expectations, creating a dynamic environment that demands precise, evidence-based decision making. Advances in imaging modalities, software analytics, and care delivery models are reshaping how clinicians detect and manage early-stage disease, while regulatory frameworks and payer priorities are aligning to emphasize value, outcomes, and equitable access. Concurrently, evolving awareness campaigns and risk-stratified approaches have intensified demand for more sensitive, less invasive, and patient-friendly screening pathways.

Against this backdrop, the ecosystem that supports screening-manufacturers, hospital systems, ambulatory centers, diagnostic chains, software vendors, and payers-must reconcile competing pressures: the need to adopt high-performance technologies that improve diagnostic accuracy, the imperative to control costs and integrate with electronic workflows, and the requirement to demonstrate clinical utility and workforce readiness. Technological convergence, including the integration of advanced image reconstruction, multiplanar visualization, and intelligent algorithms, is accelerating the clinical uptake of modalities that were once confined to tertiary centers. Meanwhile, cloud-enabled delivery modes and software-as-a-service options are lowering barriers to deployment of advanced analytics and facilitating remote reading and second-opinion workflows.

The introduction sets the stage for a detailed exploration of transformational shifts, regulatory and trade headwinds, segmentation-specific dynamics, regional differentiation, competitive behavior, and pragmatic recommendations. It is designed to inform strategic planning by executives, clinical leaders, product teams, and procurement specialists seeking to position their organizations to capture clinical value, support scalable service models, and improve patient pathways without compromising on quality or compliance.

Pivotal transformative shifts accelerating clinical adoption of advanced imaging, AI integration, personalized screening pathways and distributed cloud-enabled care models

The past few years have produced a series of transformative shifts that are redefining what effective and equitable breast cancer screening looks like in clinical practice and in market dynamics. One of the most consequential shifts is the rapid clinical adoption of volumetric and tomographic imaging techniques, which when combined with sophisticated post-processing and reading workflows, have materially improved lesion conspicuity and reduced recall rates. These imaging advances are complemented by the maturation of artificial intelligence and machine learning algorithms that augment radiologist performance, streamline triage pathways, and optimize the allocation of scarce diagnostic expertise across distributed networks.

Another foundational shift is the movement toward personalized, risk-based screening pathways. Rather than one-size-fits-all intervals and modalities, screening programs are increasingly calibrated using a combination of clinical risk factors, genetic predispositions, and prior imaging history. This has catalyzed interest in adjunctive modalities for selected cohorts, including contrast-enhanced MRI for high-risk individuals and molecular imaging techniques for dense-breast populations where traditional mammography has limitations. In parallel, delivery models are evolving: cloud-enabled platforms and software-as-a-service offerings have accelerated the decentralization of advanced analytics and enabled remote interpretation, while automated and point-of-care hardware variants are expanding access in ambulatory centers and community clinics.

Workforce transformation and clinical training are also reshaping the landscape. As imaging complexity grows, so does the need for multidisciplinary collaboration, standardized reporting, and robust quality assurance programs. Regulatory emphasis on interoperability, data privacy, and evidence of clinical benefit has heightened the bar for new product adoption, incentivizing vendors to generate stronger real-world evidence and to engage payers earlier. Collectively, these shifts are creating a screening ecosystem that is more technology-driven, more patient-centric, and more focused on demonstrable outcomes than in previous eras.

Cumulative implications of United States tariffs enacted in 2025 on procurement, manufacturing footprints, supply chain resilience and software-led clinical continuity

The imposition of tariffs by the United States in 2025 has introduced a set of cumulative effects that are reverberating across the breast cancer screening value chain, influencing procurement strategies, vendor sourcing, manufacturing footprints, and clinical adoption timelines. Increased import costs for key subsystems, such as detectors, digital acquisition electronics, specialized pumps and coils, and the semiconductor components embedded in advanced imaging platforms, have pressured equipment vendors to rethink supply chain redundancy and component sourcing. These pressures have incentivized some manufacturers to accelerate regional manufacturing or supplier diversification while compressing product roadmaps to prioritize modular upgrades over full-system replacements.

Procurement decision-makers within hospitals, diagnostic centers, and ambulatory care settings have responded by extending equipment life cycles where clinically feasible and by negotiating multi-year service and upgrade agreements that can mitigate near-term capital cost inflation. At the same time, smaller and independent diagnostic operators have sought alternative delivery models, shifting demand toward cloud-based software subscriptions and managed services that reduce upfront capital exposure. The tariffs have also amplified the importance of software-driven diagnostic enhancements that can be deployed on existing hardware platforms, enabling providers to extract incremental clinical value without undertaking full equipment replacements.

Regulatory and payer stakeholders have become more attentive to the downstream implications of supply chain disruptions on access to care and the consistency of screening programs. In response, some health systems have prioritized investments in clinical training, cross-platform compatibility, and contingency stocking of critical spare parts to preserve service continuity. Finally, the macroeconomic signal sent by tariffs has affected investor and partnership behavior, prompting some vendors to reassess geographic expansion strategies and to seek manufacturing collaborations in markets with more favorable trade terms. The net effect is a reconfiguration of strategic priorities across manufacturers, service providers, and health systems that emphasizes resilience, software-led differentiation, and flexible procurement models.

Actionable segmentation insights revealing modality-specific trajectories, age-tailored pathways, delivery-mode differentiation and end-user adoption dynamics across care settings

Segment-specific dynamics are crucial for understanding where clinical value is created and where adoption friction persists across the breast cancer screening continuum. Technology segmentation reveals distinct adoption trajectories: two-dimensional mammography remains a foundational screening modality with analog and digital variants still in operation alongside the increasing uptake of three-dimensional tomosynthesis for improved detection in complex breast anatomy. Magnetic resonance imaging continues to diversify with contrast-enhanced protocols and non-contrast techniques being deployed according to patient risk profiles and clinical indications. Molecular breast imaging, including breast-specific gamma imaging and scintimammography, is gaining selective traction as an adjunct in cases of dense tissue where traditional x-ray-based modalities are challenged. Thermography and ultrasound modalities present differentiated roles; automated ultrasound platforms and handheld devices serve complementary diagnostic purposes and extend access in ambulatory and community settings.

Age group segmentation underscores the need for differentiated pathways: younger cohorts and those under forty often require diagnostic-focused imaging due to symptom-driven evaluation and genetic risk, while middle-aged groups typically represent the core screening population with modality selection influenced by breast density and prior imaging history. Older cohorts may face different trade-offs between sensitivity and the risks associated with overdiagnosis, necessitating nuanced shared decision-making processes. Delivery-mode segmentation is shaping deployment and operational models: on-premise solutions remain essential for high-throughput imaging centers and integrated hospital systems, whereas cloud-based offerings, including software-as-a-service and web-based platforms, are enabling distributed reading workflows, centralized quality control, and incremental adoption of advanced analytics without significant capital outlay. End-user segmentation highlights the different adoption drivers across care settings: ambulatory care centers, clinics-both primary care and specialty clinics-diagnostic centers, whether chain or independent, and hospitals, both public and private, each operate under distinct procurement cycles, clinical governance structures, and reimbursement environments. Understanding these segmentation layers in combination is essential for designing product strategies, clinical evidence generation plans, and go-to-market approaches that align with the needs and constraints of each stakeholder group.

Key regional insights on differentiated adoption patterns, reimbursement environments and access strategies across Americas, EMEA and Asia-Pacific

Regional differentiation influences technology adoption, reimbursement approaches, workforce availability, and the operational models that health systems deploy for breast cancer screening. In the Americas, there is a pronounced emphasis on consolidating advanced screening capabilities within integrated delivery networks and large diagnostic chains, coupled with growing interest in deploying AI-enabled reading platforms to manage high patient volumes and optimize recall rates. Market dynamics in this region are shaped by payer models that reward demonstrable outcomes and by centralized oncology programs that drive demand for high-sensitivity modalities in high-risk populations.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory standards, public screening program structures, and resource availability vary widely across national jurisdictions. In parts of this region, organized population-based screening programs and universal coverage models have accelerated the adoption of standardized protocols and quality assurance frameworks, while in others, infrastructure and workforce constraints have fostered innovation in portable, lower-cost modalities and tele-radiology services that bridge gaps in access.

Asia-Pacific demonstrates a blend of high-capacity tertiary centers equipped with the latest imaging platforms and rapidly expanding community-level diagnostic services that prioritize accessibility and cost-effectiveness. In several markets, public health initiatives and private sector expansion are simultaneously increasing screening uptake, which in turn has stimulated demand for cloud-enabled workflows, AI-driven triage tools, and scalable ultrasound solutions that can be deployed in both urban and semi-urban contexts. Across regions, the balance between centralized specialist services and decentralized community access will continue to shape investment priorities and partnership models.

Strategic company-level insights on differentiation through integration, modular upgradability, clinical evidence generation and cloud-enabled service models

Competitive dynamics in the breast cancer screening ecosystem are defined by a diverse set of participants spanning imaging equipment manufacturers, specialized software vendors, cloud service providers, managed service firms, and clinical service networks. Leaders are differentiating through integrated solutions that combine hardware performance with advanced analytics, robust clinical evidence packages, and lifecycle service capabilities that reduce total cost of ownership. Strategic partnerships between device manufacturers and software innovators have become an effective route to accelerate time-to-market for AI-enabled features and to bridge clinical validation gaps through collaborative studies.

Another important trend among companies is the emphasis on modularity and upgradability, which allows customers to incrementally adopt advanced capabilities while preserving existing capital investments. This approach has been particularly attractive in environments where capital budgets are constrained or where tariff-related procurement volatility has heightened the appeal of software-driven clinical improvement. Service providers and managed-read vendors are capitalizing on cloud delivery and subscription models to offer scalable reading capacity, centralized quality assurance, and performance analytics that are valuable to both large hospital networks and independent diagnostic centers.

Finally, corporate strategies are increasingly focused on demonstrating real-world clinical impact and payer-relevant outcomes. Companies that invest in prospective clinical studies, health-economic analyses, and collaborative evidence generation with leading clinical centers are better positioned to influence guideline development and payer coverage decisions. As a result, a bifurcation is emerging between firms that emphasize incremental feature improvements and those that pursue deeper clinical validation and integrated care pathways as a route to sustained differentiation.

Practical and actionable recommendations for industry leaders to accelerate adoption, build resilience, and demonstrate clinical and payer-relevant value

Industry leaders seeking to maintain and grow their positions in the breast cancer screening arena should pursue a set of pragmatic, evidence-driven actions that align commercial objectives with clinical priorities and operational realities. First, prioritize clinical evidence generation that is prospective, multi-center, and aligned to payer endpoints so that product claims are supported by robust data demonstrating diagnostic performance, workflow efficiency, and downstream clinical impact. Second, adopt a modular product and commercial strategy that enables providers to incrementally upgrade capabilities-software analytics, AI modules, and cloud services-without requiring wholesale replacement of imaging systems, thereby lowering adoption barriers and preserving customer relationships.

Third, strengthen supply chain resilience by diversifying component sourcing, exploring regional manufacturing partnerships, and developing service models that minimize downtime and ensure continuity of diagnostic services during disruptions. Fourth, invest in training and change management programs that support radiologists, technologists, and referring clinicians in integrating new modalities and AI-assisted workflows; such investments accelerate adoption, improve diagnostic consistency, and enhance patient satisfaction. Fifth, actively engage with regulatory bodies, guideline committees, and payers to communicate real-world evidence and to shape reimbursement paradigms that reward value and outcomes rather than procedural volume. Sixth, pursue strategic collaborations across the ecosystem-academic centers, specialty clinics, chains of diagnostic centers, and technology partners-to co-develop clinical pathways, pilot new care models, and validate value propositions in representative clinical environments. By executing on these priorities, industry leaders can reduce friction in adoption, demonstrate measurable clinical benefit, and position their offerings for sustainable uptake across diverse care settings.

Rigorous mixed-methods research methodology combining secondary evidence, stakeholder interviews and triangulation to validate clinical and commercial insights

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure that insights are robust, replicable, and relevant to decision-makers across the ecosystem. The approach begins with comprehensive secondary research drawing from peer-reviewed literature, clinical guidelines, regulatory filings, patent landscapes, and company disclosures to build a contextual foundation and identify key technology, regulatory, and reimbursement trends. This is followed by primary research, including structured interviews and consultations with a cross-section of stakeholders such as radiologists, hospital procurement officers, diagnostic center managers, technology vendors, payers, and clinical investigators, to validate assumptions, uncover adoption drivers, and surface operational constraints.

Data triangulation is applied to reconcile diverse inputs and to ensure internal consistency; clinical claims and product capabilities are cross-referenced with published studies and expert commentary. Segmentation frameworks are developed and iteratively refined through stakeholder validation to reflect real-world decision processes across technology, age cohorts, delivery modes, and end-user types. Quality assurance includes methodological audits, peer review by subject-matter experts, and sensitivity checks on key qualitative inferences. Finally, findings are synthesized into actionable narratives and strategic imperatives that are designed to support procurement decisions, product development roadmaps, clinical adoption strategies, and policy engagement initiatives.

Concluding synthesis that integrates technological, clinical and strategic imperatives to guide stakeholders toward impactful screening adoption and access improvements

In conclusion, breast cancer screening is undergoing a period of substantive transformation driven by technological advancement, the ascendancy of data-driven solutions, and evolving clinical paradigms that emphasize personalized care and measurable outcomes. The confluence of volumetric imaging, AI-enabled analytics, diversified delivery models, and increasingly sophisticated evidence expectations has created both opportunities and challenges for stakeholders across the value chain. Providers and vendors that align around modular, evidence-backed solutions and invest in workforce readiness and supply chain resilience will be best positioned to translate innovation into sustained improvements in early detection and patient outcomes.

Looking forward, the strategic focus should remain on integrating new capabilities within existing clinical workflows, demonstrating comparative clinical value in relevant patient cohorts, and crafting procurement and reimbursement narratives that reflect long-term outcomes and system-level efficiencies. By prioritizing these elements-clinical validation, flexible deployment, regional sensitivity, and pragmatic engagement with payers and policymakers-stakeholders can navigate trade headwinds, scale access to high-performance screening modalities, and ultimately contribute to earlier detection and better patient trajectories across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Clinical integration of AI-powered mammography algorithms to improve diagnostic accuracy and reduce false positives
  • 5.2. Adoption of contrast-enhanced mammography techniques for more precise tumor visualization in dense breast tissue
  • 5.3. Expansion of liquid biopsy screening solutions for noninvasive detection of early-stage breast cancer biomarkers
  • 5.4. Deployment of portable ultrasound systems in underserved regions to enhance access to real-time breast imaging
  • 5.5. Development of home-based self-sampling kits for circulating tumor DNA analysis in breast cancer screening
  • 5.6. Government initiatives to implement risk-based personalized screening schedules for high-risk populations
  • 5.7. Integration of telemammography platforms to facilitate remote expert consultations in rural healthcare settings
  • 5.8. Emergence of deep learning triage tools for prioritizing abnormal mammograms and reducing radiologist workload
  • 5.9. Implementation of value-based reimbursement models incentivizing early detection and quality of breast cancer screening
  • 5.10. Post-pandemic screening catch-up programs leveraging mobile mammography units to address screening backlogs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Screening Market, by Technology

  • 8.1. 2D Mammography
    • 8.1.1. Analog
    • 8.1.2. Digital
  • 8.2. 3D Tomosynthesis
  • 8.3. Magnetic Resonance Imaging
    • 8.3.1. Contrast Enhanced
    • 8.3.2. Non Contrast
  • 8.4. Molecular Breast Imaging
    • 8.4.1. Breast Specific Gamma Imaging
    • 8.4.2. Scintimammography
  • 8.5. Thermography
  • 8.6. Ultrasound
    • 8.6.1. Automated
    • 8.6.2. Handheld

9. Breast Cancer Screening Market, by Age Group

  • 9.1. 40 To 49
  • 9.2. 50 To 69
  • 9.3. 70 And Above
  • 9.4. Under 40

10. Breast Cancer Screening Market, by Delivery Mode

  • 10.1. Cloud
    • 10.1.1. Software As A Service
    • 10.1.2. Web Based
  • 10.2. On Premise

11. Breast Cancer Screening Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
    • 11.2.1. Primary Care Clinics
    • 11.2.2. Specialty Clinics
  • 11.3. Diagnostic Centers
    • 11.3.1. Chain Centers
    • 11.3.2. Independent Centers
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals

12. Breast Cancer Screening Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Breast Cancer Screening Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Breast Cancer Screening Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Hologic, Inc.
    • 15.3.2. GE HealthCare
    • 15.3.3. Siemens Healthineers AG
    • 15.3.4. Koninklijke Philips N.V.
    • 15.3.5. Fujifilm Holdings Corporation
    • 15.3.6. Canon Medical Systems Corporation
    • 15.3.7. Konica Minolta, Inc.
    • 15.3.8. Shimadzu Corporation
    • 15.3.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 15.3.10. Carestream Health, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BREAST CANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BREAST CANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BREAST CANCER SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BREAST CANCER SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2025-2032 (USD MILLION)

TABLE 311.